Display options
Cite
Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015;8:3783-92doi: 10.2147/OTT.S95470.
Xu, H., Tian, Y., Yuan, X., Wu, H., Liu, Q., Pestell, R. G., & Wu, K. (2015). The role of CD44 in epithelial-mesenchymal transition and cancer development. OncoTargets and therapy, 83783-92. https://doi.org/10.2147/OTT.S95470
Xu, Hanxiao, et al. "The role of CD44 in epithelial-mesenchymal transition and cancer development." OncoTargets and therapy vol. 8 (2015): 3783-92. doi: https://doi.org/10.2147/OTT.S95470
Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, Wu K. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015 Dec 16;8:3783-92. doi: 10.2147/OTT.S95470. eCollection 2015. PMID: 26719706; PMCID: PMC4689260.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Dec 16;8:3783-92. doi: 10.2147/OTT.S95470. eCollection 2015.

The role of CD44 in epithelial-mesenchymal transition and cancer development.

OncoTargets and therapy

Hanxiao Xu, Yijun Tian, Xun Yuan, Hua Wu, Qian Liu, Richard G Pestell, Kongming Wu

Affiliations

  1. Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
  2. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

PMID: 26719706 PMCID: PMC4689260 DOI: 10.2147/OTT.S95470

Abstract

CD44, a multi-structural and multifunctional transmembrane glycoprotein, was initially identified as a receptor for hyaluronan that participates in both physiological and pathological processes. CD44 is found to be closely linked to the development of various solid tumors. Molecular studies have revealed that high CD44 expression was correlated with the phenotypes of cancer stem cells and epithelial-mesenchymal transition, thereby contributing to tumor invasion, metastasis, recurrence, and chemoresistance. Correspondingly, blockade of CD44 has been demonstrated to be capable of attenuating the malignant phenotype, slowing cancer progression, and reversing therapy resistance. Clinical analyses showed that high CD44 expression is associated with poor survival of various cancer patients, indicating that CD44 can be a potential prognostic marker. In this review, we summarize recent research progress of CD44 on tumor biology and the clinical significance of CD44.

Keywords: CD44; epithelial–mesenchymal transition; prognosis; tumor progression

References

  1. Mol Cancer Res. 2015 Jan;13(1):9-15 - PubMed
  2. Am J Respir Cell Mol Biol. 2011 Mar;44(3):377-83 - PubMed
  3. PLoS One. 2010 Nov 19;5(11):e14062 - PubMed
  4. J Biol Chem. 2009 May 1;284(18):12432-46 - PubMed
  5. Int J Cancer. 2015 Feb 15;136(4):E161-72 - PubMed
  6. Breast Cancer Res. 2012 May 23;14(3):R84 - PubMed
  7. Oncotarget. 2015 Aug 14;6(23):19634-46 - PubMed
  8. Oncotarget. 2015 Nov 3;6(34):36762-73 - PubMed
  9. Gut Liver. 2011 Dec;5(4):397-405 - PubMed
  10. Int J Mol Sci. 2014 Feb 27;15(3):3560-79 - PubMed
  11. Am J Physiol Cell Physiol. 2015 Jan 1;308(1):C68-78 - PubMed
  12. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 - PubMed
  13. Oncogene. 2011 Nov 24;30(47):4707-20 - PubMed
  14. Nat Med. 2006 Oct;12(10):1167-74 - PubMed
  15. Tumour Biol. 2014 Jun;35(6):5953-63 - PubMed
  16. J Biol Chem. 2002 Feb 15;277(7):4589-92 - PubMed
  17. Int J Oncol. 2014 Mar;44(3):693-9 - PubMed
  18. Int J Oncol. 2012 Jun;40(6):1858-64 - PubMed
  19. Int J Cancer. 2015 Sep 15;137(6):1279-90 - PubMed
  20. Int J Oncol. 2012 Apr;40(4):1171-9 - PubMed
  21. Cell Biochem Funct. 2011 Jun;29(4):303-10 - PubMed
  22. Mol Cell Biol. 2012 Aug;32(16):3293-307 - PubMed
  23. Oncol Rep. 2013 Apr;29(4):1570-8 - PubMed
  24. Cancer. 2001 Nov 15;92(10):2539-46 - PubMed
  25. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5 - PubMed
  26. FEBS J. 2011 May;278(9):1429-43 - PubMed
  27. J Hepatobiliary Pancreat Sci. 2013 Apr;20(4):429-34 - PubMed
  28. Oncotarget. 2014 Nov 15;5(21):10803-15 - PubMed
  29. Arch Dermatol Res. 2013 Jan;305(1):35-47 - PubMed
  30. J Int Med Res. 2015 Apr;43(2):173-9 - PubMed
  31. Cancer Sci. 2004 Dec;95(12):930-5 - PubMed
  32. Cell Signal. 2013 Dec;25(12 ):2625-33 - PubMed
  33. Immunology. 1988 May;64(1):37-43 - PubMed
  34. Genes Dev. 2009 Aug 1;23 (15):1737-42 - PubMed
  35. Breast Cancer Res. 2012 Jul 12;14(4):R105 - PubMed
  36. Mol Biol Cell. 2010 Dec;21(24):4387-99 - PubMed
  37. Cancer Res Treat. 2016 Jan;48(1):142-52 - PubMed
  38. Mol Cancer Ther. 2014 May;13(5):1270-84 - PubMed
  39. World J Surg Oncol. 2014 Dec 02;12:368 - PubMed
  40. PLoS One. 2014 Nov 03;9(11):e111783 - PubMed
  41. Clin Cancer Res. 2008 Nov 1;14 (21):6751-60 - PubMed
  42. Oncotarget. 2015 May 10;6(13):11465-76 - PubMed
  43. J Clin Invest. 2011 Mar;121(3):1064-74 - PubMed
  44. Biomed Res Int. 2014;2014:760303 - PubMed
  45. Int J Cancer. 2015 Apr 1;136(7):1504-14 - PubMed
  46. Eur J Cancer. 2014 Jan;50(2):366-78 - PubMed
  47. Saudi Med J. 2015 Mar;36(3):273-9 - PubMed
  48. Cell. 2008 May 16;133(4):704-15 - PubMed
  49. Am J Clin Pathol. 2002 Jul;118(1):67-72 - PubMed
  50. Curr Pharm Biotechnol. 2011 Feb 1;12(2):196-205 - PubMed
  51. J Virol. 2011 Nov;85(21):11255-64 - PubMed
  52. Oncogene. 2015 Oct 8;34(41):5229-39 - PubMed
  53. Oncotarget. 2015 Apr 20;6(11):9313-26 - PubMed
  54. Breast Cancer Res Treat. 2014 Jan;143(1):11-8 - PubMed
  55. J Exp Clin Cancer Res. 2014 Dec 31;33:779 - PubMed
  56. J Hematol Oncol. 2014 Apr 16;7:34 - PubMed
  57. Mol Cancer Res. 2014 Oct;12 (10 ):1416-29 - PubMed
  58. Cancer Res. 2014 May 1;74(9):2630-41 - PubMed
  59. Onco Targets Ther. 2015 Jun 03;8:1327-34 - PubMed
  60. Oral Oncol. 2012 Jan;48(1):1-9 - PubMed
  61. Lab Invest. 2014 Dec;94(12):1370-81 - PubMed
  62. Genes Dev. 2015 Jan 15;29(2):171-83 - PubMed
  63. Front Immunol. 2015 May 06;6:201 - PubMed
  64. Zhonghua Zhong Liu Za Zhi. 2010 Jan;32(1):22-8 - PubMed
  65. Oncol Rep. 2012 May;27(5):1599-605 - PubMed
  66. Clin Exp Metastasis. 2009;26(5):433-46 - PubMed
  67. Am J Clin Pathol. 2001 Jul;116(1):122-8 - PubMed
  68. Prostate. 2014 May;74(6):602-17 - PubMed
  69. BMC Cancer. 2010 Aug 10;10:414 - PubMed
  70. Breast Cancer Res Treat. 2012 Jun;133(3):979-95 - PubMed
  71. Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 - PubMed
  72. EMBO J. 2011 Jun 24;30(15):3186-99 - PubMed
  73. Cell Signal. 2015 Sep;27(9):1882-94 - PubMed
  74. Onco Targets Ther. 2014 Oct 20;7:1933-44 - PubMed
  75. Mol Cancer. 2014 Feb 24;13:37 - PubMed
  76. Adv Exp Med Biol. 2009;656:85-106 - PubMed
  77. Oncotarget. 2015 Jan 20;6(2):1202-16 - PubMed
  78. BMC Cancer. 2010 Aug 06;10 :411 - PubMed
  79. J Biol Chem. 2012 Oct 19;287(43):36435-42 - PubMed
  80. Oncotarget. 2014 Nov 15;5(21):10840-53 - PubMed
  81. PLoS One. 2013 Dec 30;8(12):e83971 - PubMed
  82. Ultrastruct Pathol. 2011 Apr;35(2):72-8 - PubMed
  83. Stem Cell Res. 2014 Jan;12 (1):86-100 - PubMed
  84. BMC Cancer. 2011 Feb 01;11:49 - PubMed
  85. Neuro Oncol. 2014 May;16(5):671-85 - PubMed
  86. Int J Oncol. 2012 Jul;41(1):211-8 - PubMed
  87. Front Oncol. 2015 Aug 10;5:180 - PubMed
  88. Oncotarget. 2014 Nov 30;5(22):11669-80 - PubMed
  89. Cancer Res. 2005 Jul 1;65(13):5812-7 - PubMed
  90. Exp Mol Pathol. 1999 Apr;66(1):99-108 - PubMed
  91. J Hematol Oncol. 2014 Mar 31;7:29 - PubMed
  92. Adv Cancer Res. 1997;71:241-319 - PubMed
  93. PLoS One. 2014 Nov 14;9(11):e112580 - PubMed
  94. Stem Cell Reports. 2013 Dec 27;2(1):78-91 - PubMed

Publication Types

Grant support